Lynch Syndrome: Clinical Trials

7 trials for Lynch Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 recruiting, 1 not yet recruiting, 1 terminated. 7 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Active not recruiting 2, Recruiting 2, Not yet recruiting 1, Terminated 1, Unknown 1
Phase 12Active not recruiting 1, Not yet recruiting 1

Follow Lynch Syndrome: new trials by email Literature Review of Lynch Syndrome trials Research Report on Lynch Syndrome

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Preventive Dendritic Cell Vaccination for Lynch Syndrome
DC vaccination - Lynch Syndrome
Phase 1 / Phase 2Not yet recruitingRadboud University Medical Center162026-10-012026-08-19
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Biopsy Procedure, Biospecimen Collection - Colorectal Carcinoma, Colorectal Neoplasm
Phase 2Active not recruitingNational Cancer Institute (NCI)1862023-05-082026-11-12
A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome
Naproxen, Aspirin - T Cells, Colorectal Cancer
Phase 2RecruitingM.D. Anderson Cancer Center402023-03-212026-11-05
Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Biospecimen Collection, Endoscopic Biopsy - Colorectal Carcinoma, Lynch Syndrome
Phase 1 / Phase 2Active not recruitingNational Cancer Institute (NCI)452022-11-102026-03-03
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
Mesalamine, Placebo - Lynch Syndrome, Colon Cancer
Phase 2RecruitingAnn-Sofie Backman1502022-03-212024-12-17
Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)
Omega-3 fatty acid ethyl esters (2 gram) - Colorectal Cancer, Lynch Syndrome
Phase 2UnknownUniversity of Kansas Medical Center212019-02-062023-06-01
Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy
Nivolumab - Colon Adenoma, Colon Carcinoma
Phase 2TerminatedJohn Hays32018-10-042024-07-01

Narrower conditions

Colorectal Neoplasms, Hereditary Nonpolyposis (7)  ·  Colorectal Neoplasms (4)  ·  Colonic Neoplasms (2)

Broader conditions

Colonic Diseases (7)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7)  ·  DNA Repair-Deficiency Disorders (7)  ·  Digestive System Diseases (7)  ·  Digestive System Neoplasms (7)  ·  Gastrointestinal Diseases (7)  ·  Gastrointestinal Neoplasms (7)  ·  Genetic Diseases, Inborn (7)  ·  Intestinal Diseases (7)  ·  Intestinal Neoplasms (7)  ·  Metabolic Diseases (7)  ·  Neoplasms (7)  ·  Neoplasms by Site (7)  ·  Neoplastic Syndromes, Hereditary (7)  ·  Nutritional and Metabolic Diseases (7)

Interventions

Biopsy (2)  ·  Specimen Handling (2)  ·  Aspirin (1)  ·  Colonoscopy (1)  ·  Endoscopic Mucosal Resection (1)  ·  Endoscopy (1)  ·  Mesalamine (1)  ·  Naproxen (1)  ·  Nivolumab (1)  ·  Omacor (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  Ann-Sofie Backman (1)  ·  John Hays (1)  ·  M.D. Anderson Cancer Center (1)  ·  Radboud University Medical Center (1)  ·  University of Kansas Medical Center (1)

Countries

United States (5)  ·  Puerto Rico (2)  ·  Denmark (1)  ·  Netherlands (1)  ·  Sweden (1)

Top investigators

Ajay Bansal (1)  ·  Ann-Sofie Backman, MD PhD (1)  ·  Anwaar Saeed, MD (1)  ·  Eduardo Vilar-Sanchez (1)  ·  Eduardo Vilar-Sanchez, MD (1)  ·  John Hays, MD, Ph.D (1)

Results publications

PMID 41213710, PMID 41545594, PMID 42238576

NIH funding

UG1CA242609 (2), P30CA016672 (1), P30CA060553 (1), R01CA257375 (1), UG1CA242596 (1), UG1CA242632 (1), UG1CA242635 (1), UG1CA242643 (1)